Skip to main content


What is your government up to? And, what does it mean for your drug spend?

A discussion with General Counsel Natalie Pons and Sr Director Pipeline & Surveillance Bill Dreitlein


The current year promises to hold changes that could profoundly impact the pharmacy benefit. State legislatures are already moving quickly. Optum Rx is tracking hundreds of legislative proposals, including point-of-sale rebates, anti-steering, network reimbursement and accreditation limitations, and the use of evidence-based clinical management tools.

In this lively discussion, Natalie Pons will weigh in on a range of hot-button regulatory issues that could potentially impact the choices you make to best manage your drug spend. She’ll be joined by Bill Dreitlein, who will discuss topics including interchangeable biosimilars, the impact of COVID-19 vaccines moving under the pharmacy benefit as well as ways the pandemic has influenced the drug pipeline going forward.

This 30-minute hosted chat with our experts will better prepare you for what is expected in 2022.


Host: Mike McGinnity, Optum Rx Senior Vice President, Consultant Partnerships

Guests: Natalie Pons, General Counsel and Bill Dreitlein, Sr. Director Drug Pipeline & Surveillance, Optum Rx

Please complete the form to watch.

When you're ready to talk to an expert, contact us.